PHE - Corporate - A Clinical and Cost Effectiveness Model on Formalising New-born Screening for β-thalassaemia Major
Commissioning document: Formalising screening for β-thalassaemia major as part of the newborn blood spot screening programme for sickle cell disease: a clinical and cost-effectiveness model
Buyer
Public Health England
Value
£81,463
Published
3 Nov 2020
Closes
14 Oct 2020
Procurement details
Source
Contracts Finder
Region
United Kingdom
Procurement method
Other Competition From Framework
Category
Services
Contract starts
2 Nov 2020
Contract ends
29 Apr 2022
CPV classifications
75122000
Administrative healthcare services
Lots
Lot default PHE - Corporate - A Clinical and Cost Effectiveness Model on Formalising New-born Screening for β-thalassaemia Major
£81,463
Commissioning document: Formalising screening for β-thalassaemia major as part of the newborn blood spot screening programme for sickle cell disease: a clinical and cost-effectiveness model
Delivery: British Oversea Territories, Channel Islands, Europe, Isle of Man, Rest of the World, United Kingdom
Documents
Unlock document linkAwarded contract notice on Contracts Finder
3 Nov 2020
Awarded contract notice on Contracts Finder
Award notice · Web page
Contains public sector information licensed under the Open Government Licence v3.0.